Stockscreener 앱 받기
1.33
5.56%
0.07
전일 마감가:
$1.26
열려 있는:
$1.26
하루 거래량:
9,067
Relative Volume:
0.28
시가총액:
$11.16M
수익:
-
순이익/손실:
-
주가수익비율:
-1.8754
EPS:
-0.7092
순현금흐름:
-
1주 성능:
+2.13%
1개월 성능:
-4.32%
6개월 성능:
-24.43%
1년 성능:
-48.85%
1일 변동 폭
$1.231
$1.338
1주일 범위:
$1.231
$1.338
52주 변동 폭
$1.01
$5.41
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
Alterity Therapeutics announces regulatory notice filing - Investing.com
Alterity Therapeutics announces regulatory notice filing - Investing.com India
ATHE’s Stock Market Adventure: -14.26% YTD Growth Amidst Volatility - The InvestChronicle
Alterity reports positive Phase 2 trial interim data - Investing.com
Alterity Therapeutics announces trading halt - Investing.com
Alphabet stock cited by TD Cowen amid potential Wiz acquisition - Investing.com
Alterity Therapeutics announces trading halt By Investing.com - Investing.com
Avenue Supermarts stock target raised by Nuvama, still a Hold - Investing.com India
Wolfe Research keeps Peerperform rating on Goldman Sachs stock, notes mixed Q2 earnings - Investing.com India
RBC Capital sees growth potential in Bowhead Specialty shares - Investing.com
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar - GlobeNewswire Inc.
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study - GlobeNewswire Inc.
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review - GlobeNewswire Inc.
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report - GlobeNewswire Inc.
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia - GlobeNewswire Inc.
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Alterity Therapeutics announces trading halt By Investing.com - Investing.com India
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting - GlobeNewswire Inc.
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 - GlobeNewswire Inc.
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund - GlobeNewswire Inc.
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
ASX Health Winners December: Health stocks beat market, look ‘undervalued’ going into 2024 - Stockhead
Closing Bell: The ASX is slightly higher, but not much cooler on Monday - Stockhead
Biotech ‘to be worth $US4 trillion’ - Daily Telegraph
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
24 Stocks Moving in Friday's Pre-Market SessionAlterity Therapeutics (NASDAQ:ATHE) - Benzinga
ATHEAlterity Therapeutics Limited Latest Stock News & Market Updates - StockTitan
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
Check up: Enthusiasm rather than news is moving health stocks - Stockhead
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For An - Benzinga
54 Biggest Movers From YesterdayAcasti Pharma (NASDAQ:ACST), Alterity Therapeutics (NASDAQ:ATHE) - Benzinga
알테리티 테라퓨틱스 (ATHE) 재무 분석
알테리티 테라퓨틱스 (ATHE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.26%
1.71%
자본화:
|
볼륨(24시간):